Comparison of Software for Prediction of Fraction Absorbed and Unbound in Humans
Fagerholm, U.
Show abstract
The main objective of this study was to evaluate and compare the performance of 5 PK software, ANDROMEDA by Prosilico 2.0, and 4 free, web-based prediction tools, PkCSM, Swiss ADME, ADMETlab 3.0 and DruMAP 2.0, for predictions of fraction absorbed (fa) and unbound (fu) in humans. Sets with compounds with available and undisclosed estimates were selected (n=140). The risk that test compounds have been used in training sets for model building (and thereby, influenced and exaggerated the predictive performances) was minimized. At least, these were not included in training sets for ANDROMEDA. One set consisted of compounds that have not been marketed and for which pharmacokinetic information has not been publically disclosed. Quantitative and qualitative evaluations and comparisons were done. For both fa and fu, ANDROMEDA was clearly more accurate and balanced than the others, with higher Q2 (0.69 vs 0.35 for fa; 0.94 vs 0.62-0.76 for fu), lower mean errors (15 % vs 28 %; 2.3- vs 4.1- to 36-fold), lower maximum errors (54 % vs 92 %; 10- vs 30- to 524-fold), more correct predicted classes (70-77 % vs 13-54 %), no failed, inconclusive or poor predictions (as found for 3 of the other software), wider application range, and minimal skewness at low values. It had intercepts on fa- and fu-prediction axes that were ca 1/3 and 1/175 to 1/23 compared to those found for the other software, which is of particular importance. Two software, PkCSM and Swiss ADME, were considered inappropriate, whereas ADMETlab took an intermediate performance position. Apparently, DruMAP was second best performing software. Overall, there was poor performance overlap between the software (7-24 %), with many contradictory predictions. Advantages with ANDROMEDA suggest that this is the software of choice for those that desire adequate predictions of fa and fu in humans and estimates of certainty. The findings are of particular interest for the 3R-process.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing 94%
- PBPK modelling of dexamethasone in patients with COVID-19 and liver disease 94%
- Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan 94%
Similar papers in this journal
- DigiLoCS: A Leap Forward in Predictive Organ-on-Chip Simulations 95%
- Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: a three-part randomized, double-blind, placebo-controlled trial 94%
- Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing 93%
Similar papers in this journal
Similar papers in this journal
- Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations 94%
- Intense bitterness of molecules: machine learning for expediting drug discovery 94%
- Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.